- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Lipoprotein (a) assay methods similarly predict MACE reduction with PCSK9 inhibitor Alirocumab: Study
USA: A recent comparison of changes in lipoprotein(a) mass and molar concentrations found that each essay method is similarly predictive of major adverse cardiovascular events (MACE) reductions with alirocumab (ALI).
The study stated, "With caveats of a modest number of MACE for analysis, moderately elevated Lp(a) levels, and intra-patient variability in serial values, three Lp(a) assay methods appeared comparably predictive of ALI MACE reduction, independent of reduction in LDL cholesterol,"
The findings were published online in the European Journal of Preventive Cardiology on March 19, 2024.
Baseline (BL) lipoprotein (a) concentrations are similarly related to cardiovascular (CV) risk when measured in either molar units or mass by immunoassay (IA). Because of Lp(a) isoform variation in mass, there may be differences between Lp(a) measurement methods in terms of relating change to risk reduction.
Against the above background, Michael Szarek, Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA, and colleagues determined whether the reduction in MACE by PCSK9 inhibitor alirocumab has a similar relationship to the reduction in Lp (a) concentration as measured by three different methods.
Lipoprotein (a) was measured by IA-molar (Roche), IA-mass (Siemens), and mass spectrometry (MS)-molar assays at baseline and month 4 (M4) in a subgroup of patients in the ODYSSEY OUTCOMES trial. The trial compared PCSK9 inhibitor ALI with placebo in patients with recent acute coronary syndrome.
Changes in Lp(a) from baseline to M4 were related to subsequent risk of MACE (nonfatal myocardial infarction, coronary heart disease death, unstable angina hospitalization, or fatal + nonfatal ischemic stroke) in the ALI group. Proportional hazard models were adjusted for baseline Lp(a), baseline LDL-C and its change from BL to M4, and other patient characteristics. Hazard ratios (HR) were calculated for the median change of each Lp(a) assay.
The study led to the following findings:
- Among 5500 patients randomized to ALI with available data from all 3 Lp(a) assays, 443 experienced a subsequent MACE.
- Changes in Lp(a) IA-mass and MS-molar concentration were significantly related to reduced MACE risk, while a change in IA-molar concentration was marginally significant; associations were more evident with coronary heart disease death + nonfatal MI.
- MACE HRs for median change were similar across tests.
In conclusion, despite the relatively low number of MACE available for analysis, only moderately elevated lipoprotein levels, and intra-patient variability in serial value, the researchers showed that each of the 3 Lp(a) assay methods was similarly predictive of modest MACE reductions with alirocumab treatment.
"Greater clinical benefits might be observed, with the emergence of new potent Lp(a) lowering agents," the researchers wrote.
Reference:
Szarek, M., Reijnders, E., Steg, P. G., Jukema, J. W., Schwertfeger, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., White, H. D., Zeiher, A. M., Cobbaert, C., & Schwartz, G. G. Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwae110
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751